Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Jul 25, 2022 12:52pm
201 Views
Post# 34848543

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CR at 450

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CR at 450Consultant99 ... We already had/have some answers from NML so far.

Will it be quicker to make? sounds like yes as per a comment by Dr. Kobasa
Will it be cheaper to make store and transport?  sounds like yes
Will it have greater efficacy? sounds like yes, given it destroys the virus envelopes
Will it be safer? yes given the low dose (nano molecular dose) hinted by Dr. Coombs and Dr. Kobasa
How adaptable to other viruses?  yes as per the comment by Dr. Kobasa mentioned in the press releases

_________________________

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CR at 450
There is a lot of potential - I 100% totally agree with you. It might not be enough to just be able to make a vaccine that works but how this novel approach compares to existing vaccines.

Will it be quicker to make?
Will it be cheaper to make store and transport?
Will it have greater efficacy?
Will it be safer?
How adaptable to other viruses?

NVAX share price went from less than $5/share to over $300 briefly during the Covid vaccine gold rush. It is not hard to imagine TLT getting a big share price boost if the current animal testing is favourable and leads to human testing of a Covid vaccine.

The next 6-9 months could be liftoff with BTD AA for bladder cancer and moving towards human testing of a Covid vaccine. Will Roger be driving the bus by then?
<< Previous
Bullboard Posts
Next >>